Drug Type Fusion protein |
Synonyms- |
Target |
Action inhibitors |
Mechanism APRIL inhibitors(Tumor necrosis factor ligand superfamily member 13 inhibitors), BAFF inhibitors(B-cell-activating factor/B lymphocyte stimulator inhibitors), BCMA inhibitors(B-cell maturation protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Glomerulonephritis, IGA | Phase 1 | China | 16 Mar 2026 | |
| Myasthenia Gravis, Ocular | IND Approval | China | 12 Jun 2026 | |
| Myasthenia Gravis | IND Approval | United States | 01 Jun 2026 | |
| Primary Sjögren's syndrome | IND Application | China | 01 Dec 2025 | |
| Systemic Lupus Erythematosus | IND Application | China | 01 Dec 2025 |






